Join Corbus Pharmaceuticals for a conference call to discuss topline data for CANYON‑1, a Phase 1b study of CRB‑913 for the treatment of obesity. The event will feature Harold Bays, MD, an investigator of the study.

The Company will provide an overview of CRB‑913, a once-daily highly peripherally restricted oral CB1 inverse agonist potentially offering an orthogonal approach to weight loss and long-term weight management and a new therapeutic option for obesity beyond GLP‑1 and other incretin-targeting therapies. Management will also review the CANYON‑1 Phase 1b clinical trial, a 16‑week double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic adult participants conducted at multiple clinical sites in the United States (NCT07310901).

A live question and answer session will follow the formal presentations.